Graves' Disease Market to Grow Due to Rising Thyroid Disorder Prevalence
![]() |
Graves' Disease Market |
The Graves’ disease overactive thyroid market is a segment of the broader thyroid disorder therapeutics industry. Graves' disease, also known as toxic diffuse goiter or toxic adenomatous goiter, is an autoimmune disease that leads to the overproduction of thyroid hormones in the body. Uncontrolled thyroid hormones can have several adverse effects on the whole body like weight loss, cardiac issues, tremors, anxiety and many others. As per estimates, Graves' disease affects around 0.5% of the total population. With growing awareness about early diagnosis and treatment of thyroid issues coupled with the rising burden of thyroid disorders globally, the demand for Graves' disease therapeutics is expected to increase substantially over the coming years.
The Global Graves' disease overactive
thyroid market is estimated to be valued at US$ 570.2 Mn in 2024 and is expected to exhibit a CAGR of 4.8% over the forecast period
2024 to 2031.
Key
Takeaways
Key players operating in the Graves'
disease overactive thyroid market are AbbVie Inc., Pfizer Inc., RLC LABS, Inc.,
Merck KGaA, Eisai Co., Ltd., Novartis AG, Mylan N.V., Aspen Pharmacare Holdings
Ltd, Sanofi, GlaxoSmithKline plc, AstraZeneca, Horizon Therapeutics plc, Alara
Pharmaceutical Corporation, Antares Pharma, Inc., Apitope Technology (Bristol)
Ltd., IONIS Pharmaceuticals, Inc., Immunovant, Inc., HanAll Biopharma Co.,
Ltd., Cara Therapeutics.
The Graves
Disease Overactive Thyroid Market Size
offers new growth opportunities with the availability of newer treatment
options and pipeline products in development. Emerging technologies like
cell-based therapies and gene editing are also spurring innovation in Graves'
disease treatment landscape.
Major players in the Graves' disease overactive thyroid market are focusing on
geographical expansion and global facility upgrades to strengthen their market
position. Strategic partnerships and M&A activities are helping companies
augment product portfolios and improve global commercial footprints.
Market
Restraints
High cost of newer targeted drugs
remains a major challenge restricting broader patient access and uptake.
Thyroid surgeries also carry risks of recurrent laryngeal nerve injuries and
hypoparathyroidism. Social stigma associated with thyroid disorders in some
cultures acts as a behavioral barrier to timely medical intervention and
management. Strict regulatory approval processes further delay market entry of
novel treatment concepts and modalities.
Market
Drivers
One of the key drivers for the Graves'
disease overactive thyroid market size and trends is the increasing
prevalence of thyroid disorders across both developed and developing regions.
Factors like genetic predisposition, changing lifestyle patterns, growing
environmental pollution are contributing to the rising disease incidence.
Advances in diagnostic techniques are also enabling early detection of Graves'
disease, driving the adoption of therapeutic drugs and solutions.
Segment
Analysis
The Graves disease overactive thyroid market can be segmented based on treatment
type, route of administration, distribution channel and geography. Based on
treatment type, the market is divided into radioactive iodine therapy,
antithyroid drugs, and surgery. The antithyroid drugs segment currently
dominates the market owing to easy availability and less invasive nature of
drugs such as propylthiouracil, methimazole, and beta blockers. These oral
medications are prescribed long term to inhibit thyroid hormone production.
Global
Analysis
Regionally, North America is
expected to hold the largest share in the Graves disease overactive thyroid
market during the forecast period. Factors such as rising incidence of thyroid
disorders, presence of key players, developed healthcare infrastructure and
high healthcare expenditure in the US and Canada are anticipated to drive
market growth in North America. On the other hand, Asia Pacific region is
projected to witness the highest growth rate due to increasing patient
awareness about Graves disease treatment, growing geriatric population, and
improving healthcare facilities across developing economies like India and
China.
Gets
More Insights on, Graves
Disease Overactive Thyroid Market
Explore Related Article on, Chagas Disease Treatment Market
About Author:
Comments
Post a Comment